JHVEPhoto/iStock Editorial by way of Getty Pictures
Abeona Therapeutics (NASDAQ:ABEO) introduced that the FDA has accepted for evaluation Abeona’s resubmission of its Biologics License Utility for prademagene zamikeracel, its investigational autologous cell-based gene remedy, as a possible new therapy for recessive dystrophic epidermolysis bullosa.
The FDA has assigned a Prescription Drug Consumer Payment Act goal motion date of April 29, 2025.
Supply: Press Launch
